The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.

Published on Feb 1, 2019in The Journal of Urology5.925
· DOI :10.1016/J.JURO.2018.08.050
Gerald L. Andriole97
Estimated H-index: 97
(WashU: Washington University in St. Louis),
Lale Kostakoglu56
Estimated H-index: 56
(ISMMS: Icahn School of Medicine at Mount Sinai)
+ 5 AuthorsBarry A. Siegel103
Estimated H-index: 103
(WashU: Washington University in St. Louis)
Purpose:The prospective, multicenter LOCATE (18F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with 18F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent.Materials and Methods:Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were suspected to have recurrence based on rising prostate specific antigen levels were enrolled prospectively. Each man had negative or equivocal findings on standard of care imaging. 18F-fluciclovine positron emission tomography/computerized tomography was performed according to standardized protocols. Treating physicians completed a questionnaire regarding the patient treatment plan before and after scanning, recording changes to the treatment modality (eg salvage radiotherapy to systemic androgen deprivation therapy) ...
📖 Papers frequently viewed together
86 Citations
630 Citations
129 Citations
#1Walter ArtibaniH-Index: 62
#1Walter ArtibaniH-Index: 53
Last. Salvatore SiracusanoH-Index: 22
view all 5 authors...
How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR) following primary curative treatment is a controversial issue. Importantly, this prostate-specific antigen (PSA)-onl
44 CitationsSource
#1Jeffrey Goldstein (Tel Aviv Sourasky Medical Center)H-Index: 5
#2Einat Even-SapirH-Index: 44
Last. Zvi SymonH-Index: 12
view all 11 authors...
Purpose:The FDA approved C-11 choline PET/computed tomography (CT) for imaging patients with recurrent prostate cancer in 2012. Subsequently, the 2014 NCCN guidelines have introduced labeled choline PET/CT in the imaging algorithm of patients with suspected recurrent disease. However, there is only
37 CitationsSource
#1Thomas A. Hope (UCSF: University of California, San Francisco)H-Index: 39
#2Rahul Aggarwal (UCSF: University of California, San Francisco)H-Index: 26
Last. Peter R. Carroll (UCSF: University of California, San Francisco)H-Index: 141
view all 11 authors...
: The purpose of this prospective study was to estimate the effect of 68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET on the intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and postimaging surveys were filled out by the referring providers for patients with biochemical recurrence who were imaged using 68Ga-PSMA-11 PET. The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo after initi...
65 CitationsSource
We here aim to provide a comprehensive and critical review of the literature concerning the clinical applications of positron emission tomography/computed tomography (PET/CT) with radiolabeled choline in patients with prostate cancer (PCa). We will initially briefly summarize the historical context that brought to the synthesis of [11C]choline, which occurred exactly 20 years ago. We have arbitrarily grouped the clinical studies in three different periods, according to the year in which they wer...
26 CitationsSource
#1Matthew P. MillerH-Index: 6
#2Lale Kostakoglu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 56
Last. Penelope WardH-Index: 25
view all 9 authors...
: 18F-Fluciclovine is a novel PET/CT tracer. This blinded image evaluation (BIE) sought to demonstrate that, after limited training, readers naive to 18F-fluciclovine could interpret 18F-fluciclovine images from subjects with biochemically recurrent prostate cancer with acceptable diagnostic performance and reproducibility. The primary objectives were to establish individual readers' diagnostic performance and the overall interpretation (2/3 reader concordance) compared with standard-of-truth da...
22 CitationsSource
#1Nicolas MottetH-Index: 40
#2Joaquim Bellmunt (Harvard University)H-Index: 87
Last. Philip CornfordH-Index: 27
view all 22 authors...
Abstract Objective To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). Evidence acquisition The working panel performed a literature review of the new data (2013–2015). The guidelines were updated and the levels of evidence and/or gra...
1,813 CitationsSource
#1Philip CornfordH-Index: 27
#2Joaquim Bellmunt (Harvard University)H-Index: 87
Last. Nicolas MottetH-Index: 40
view all 15 authors...
Abstract Objective To present a summary of the 2016 version of the European Association of Urology (EAU) – European Society for Radiotherapy & Oncology (ESTRO) – International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). Evidence acquisition The working panel performed a literature review of the new data (2013–2015). The guidelines were updated, and the levels of evidence and/or grades of recommendatio...
770 CitationsSource
#1Ashesh B. Jani (Emory University)H-Index: 35
#2Eduard Schreibmann (Emory University)H-Index: 28
Last. David M. Schuster (Emory University)H-Index: 33
view all 13 authors...
: The purpose of this study was to evaluate the role of the synthetic amino acid PET radiotracer 18F-fluciclovine in modifying the defined clinical and treatment-planning target volumes in postprostatectomy patients undergoing salvage radiotherapy and to evaluate the resulting dosimetric consequences to surrounding organs at risk. Methods: Ninety-six patients were enrolled in a randomized, prospective intention-to-treat clinical trial for potential salvage radiotherapy for recurrent prostate can...
25 CitationsSource
#1Tore Bach-Gansmo (Oslo University Hospital)H-Index: 9
#2Cristina NanniH-Index: 54
Last. Frode Willoch (University of Oslo)H-Index: 30
view all 16 authors...
Purpose: Sensitive detection of cancer foci in men experiencing biochemical recurrence following initial treatment of prostate cancer is of great clinical significance with a possible impact on subsequent treatment choice. We describe a multisite experience of the efficacy and safety of the positron emission tomography/computerized tomography agent fluciclovine (18F) after biochemical recurrence.Materials and Methods: A total of 596 patients underwent fluciclovine (18F) positron emission tomogra...
86 CitationsSource
#1Oladunni Akin-Akintayo (Emory University)H-Index: 5
#2Ashesh B. Jani (Emory University)H-Index: 35
Last. David M. SchusterH-Index: 33
view all 12 authors...
PurposeWe explored the influence of FACBC (fluciclovine) PET/CT on the decision to offer radiotherapy and radiotherapy treatment field recommendations in postprostatectomy patients with recurrent prostate cancer.Patients and MethodsAfter obtaining institutional review board approval and informed con
39 CitationsSource
Cited By43
#1Rang Wang (Sichuan University)H-Index: 2
#2Guohua Shen (Sichuan University)H-Index: 11
Last. Rong Tian (Sichuan University)H-Index: 11
view all 0 authors...
Background Diagnosing the biochemical recurrence (BCR) of prostate cancer (PCa) is a clinical challenge, and early detection of BCR can help patients receive optimal treatment. We conducted a meta-analysis to define the diagnostic accuracy of PET/CT using 18F-labeled choline, fluciclovine, and prostate-specific membrane antigen (PSMA) in patients with BCR. Methods Multiple databases were searched until March 30, 2021. We included studies investigating the diagnostic accuracy of 18F-choline, 18F-...
#1Ali Salavati (Johns Hopkins University)H-Index: 1
#2Mehmet Gencturk (UMN: University of Minnesota)H-Index: 7
Last. Jerry W. Froelich (UMN: University of Minnesota)H-Index: 26
view all 0 authors...
PURPOSE 18F-Fluciclovine PET imaging has been increasingly used in the restaging of prostate cancer patients with biochemical recurrence (BCR); however, its clinical utility in patients with low prostate-specific antigen (PSA) levels following primary radiation therapy has not been well-studied. This study aims to determine the detection rate and diagnostic accuracy of 18F-fluciclovine PET and the patterns of prostate cancer recurrence in patients with rising PSA after initial radiation therapy,...
#1Ashesh B. Jani (Emory University)H-Index: 35
#2Eduard Schreibmann (Emory University)H-Index: 28
Last. David M. Schuster (Emory University)H-Index: 33
view all 19 authors...
Summary Background Molecular imaging is increasingly used to guide treatment decisions and planning in prostate cancer. We aimed to evaluate the role of 18F-fluciclovine-PET/CT in improving cancer control compared with conventional imaging (bone scan and either CT or MRI) alone for salvage postprostatectomy radiotherapy. Methods In EMPIRE-1, a single-centre, open-label, phase 2/3 randomised controlled trial, patients with prostate cancer with detectable PSA after prostatectomy and negative conve...
#1Soroush Rais-Bahrami (UAB: University of Alabama at Birmingham)H-Index: 48
#2Jason A. Efstathiou (Harvard University)H-Index: 55
Last. Andrew Scarsbrook (University of Leeds)H-Index: 29
view all 8 authors...
BACKGROUND A systematic literature review of the performance of 18Fluorine-fluciclovine PET/CT for imaging of men with recurrent prostate cancer was performed. METHODS Scientific literature databases (MEDLINE, ScienceDirect and Cochrane Libraries) were searched systematically during Oct 2020 using PRISMA criteria. No limit was put on the date of publication. Prospective studies reporting a patient-level 18F-fluciclovine detection rate (DR) from ≥25 patients with recurrent prostate cancer were so...
1 CitationsSource
#1Grant Harmon (LUC: Loyola University Chicago)H-Index: 4
#2Dennis Chan Md (LUC: Loyola University Chicago)
Last. Abhishek A. Solanki (LUC: Loyola University Chicago)H-Index: 11
view all 11 authors...
Abstract Purpose We used the patterns of recurrence on 18F-fluciclovine PET/CT in post-prostatectomy patients enrolled in the XXXX trial to evaluate how well the most recent NRG Oncology and Groupe Francophone de Radiotherapie Urologique (GFRU) contouring recommendations encompassed all sites of recurrence in the prostate fossa and pelvic nodes in comparison to former Radiation Therapy Oncology Group (RTOG) recommendations. Methods Patients with biochemically recurrent prostate cancer after radi...
#1Ali Baiomy (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Lucia MartiniovaH-Index: 1
Last. Gregory RavizziniH-Index: 10
view all 5 authors...
ABSTRACT A 66-year-old man with prostate adenocarcinoma status post radical retropubic prostatectomy and bilateral pelvic lymph node dissection, followed by salvage external beam radiation therapy to the prostate bed 1 year after surgery. Over the course of 17 years, the patient underwent multiple lines of systemic treatment for recurrent disease. He was referred for restaging 18F-fluciclovine PET/CT due to rising serum prostate-specific antigen levels. Contrast-enhanced 18F-fluciclovine PET/CT ...
#1Andrea Farolfi (UNIBO: University of Bologna)H-Index: 8
#2Letizia Calderoni (UNIBO: University of Bologna)H-Index: 2
Last. Paolo Castellucci (UNIBO: University of Bologna)H-Index: 54
view all 7 authors...
Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PCa) cells and several PSMA ligands for PET imaging (PSMA-PET) are now available worldwide. 68Ga-PSMA-11 has already received American Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval, and PSMA-PET is currently suggested by several international guidelines to investigate PCa in different clinical settings. In primary PCa, PSMA-PET has been shown to be superior to cross-sectional ...
#2Grace S. AhnH-Index: 1
Last. Austin R. PantelH-Index: 11
view all 6 authors...
METHODS We carried out a retrospective cohort study of patients with BR after primary treatment of PC who received imaging with 18F-fluciclovine PET/CT at our institution between January 2010 and January 2019. PET/CT results were compared with biopsy, conventional imaging results, and/or response to PC therapy. 18F-Fluciclovine PET/CT performance statistics and effects on treatment planning were calculated. RESULTS A total of 328 patients with a median age of 71 years (range, 47-90 years) and me...
#1Yingbing Wang (Harvard University)H-Index: 9
#2James A. Scott (Harvard University)H-Index: 23
Last. Edwin L. Palmer (Harvard University)H-Index: 16
view all 3 authors...